|
|
|
| Effect of Serum MMP-2 and IL-6 Levels on the Prognosis of Advanced Gastric Cancer Patients With Neoadjuvant Chemotherapy |
| Zhao Yongchun, Liu Jinyun, Liu Xiaorui |
| Department of Gastroenterology,Angang General Hospital,Anyang 455000,China |
|
|
|
|
Abstract Objective To observe the expression of serum matrix metalloproteinase-2（MMP-2）and interleukin-6（IL-6）in patients with advanced gastric cancer（AGC）,and to analyze their effects on the prognosis of neoadjuvant chemotherapy.Methods A total of 70 patients with AGC were selected,and all patients received 3 courses of neoadjuvant chemotherapy.The effect of 3 courses of treatment was observed and recorded as a short-term prognosis indicator,and the patients were divided into a poor prognosis group and a good prognosis group.The baseline data and serum MMP-2 and IL-6 levels of both groups were investigated and compared,and the effects of serum MMP-2 and IL-6 levels on the prognosis of neoadjuvant chemotherapy were analyzed.Results After 3 courses of chemotherapy,33 of the 70 patients had poor prognosis,accounting for 47.14%.Compared with the good prognosis group,the serum MMP-2 and IL-6 levels were higher of patients in the poor prognosis group（P<0.05）.Logistic regression analysis showed that the overexpression of serum MMP-2 and IL-6 at admission was an influencing factor for the poor prognosis of AGC patients with neoadjuvant chemotherapy（OR>1,P<0.05）.Conclusion The overexpression of serum MMP-2 and IL-6 suggests that patients with AGC have a higher risk of poor prognosis after neoadjuvant chemotherapy.
|
|
Received: 28 September 2021
|
|
|
|
|
|
[1] 张亚衡,龚又红,张菊英.血清肿瘤标志物对进展期胃癌新辅助化疗临床效果的监测价值[J].中国肿瘤临床与康复,2018,25(5):563-566.
[2] 刘怡,张珂诚,郗洪庆,等.胃癌新辅助化疗疗效及影响因素分析[J].解放军医学院学报,2018,39(2):117-121.
[3] 杜昕,曲泽,赵选忠,等.miRNA-126和K-Ras及MMP-7在胃癌中的表达及其相关性分析[J].实用肿瘤学杂志,2021,35(1):23-27.
[4] 高永庆,邓玉林,徐长青,等.IL-1β、IL-6、p53与胃癌组织幽门螺杆菌感染的相关性分析[J].标记免疫分析与临床,2018,25(5):79-82.
[5] 王天宝. 实用胃肠恶性肿瘤诊疗学.上卷[M].广东:广东科技出版社,2012:215.
[6] Watanabe H,Okada M,Kaji Y,et al.New response evaluation criteria in solid Tumours-Revised RECIST Guideline(Version 1.1)[J].Gan To Kagaku Ryoho,2009,36(13):2495-2501.
[7] 崔杰,杨秋敏.XELOX方案新辅助化疗治疗局部进展期胃癌的临床研究[J].实用癌症杂志,2018,33(4):606-608.
[8] 孔晋,吴文涌,吴正升.TIMP-4和MMP-2在胃癌中的表达[J].安徽医科大学学报,2020,55(6):151-155.
[9] 高杨,李盛涛,郝文伟.核桃青皮提取物调控IL-6/STAT3抑制胃癌细胞增殖和迁移的作用研究[J].河北医药,2020,42(14):2095-2099.
[10] 贺雄辉,邹科见,叶木林,等.胃癌组织MMP-2,MMP-9,Shh蛋白的表达及与临床病理特征的关系[J].医学研究杂志,2018,47(8):94-97.
[11] 董志强,刘美荣,任秀梅.IL-1β,TNF-α联合IL-6对胃癌的诊断价值[J].实用癌症杂志,2020,35(1):28-30.
[12] 顾万娟,杜希林.IL-6,TSGF联合肿瘤标记物CEA,CA724检测在胃癌中的诊断价值[J].检验医学与临床,2019,16(12):1709-1711. |
|
|
|
2023, Vol. 43 
